Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So very sorry for your loss, DD. May your memories comfort you and sustain you during this difficult time.
Doc Logic….
I hear you…if one can’t make the career change for whatever reason, start the DD and invest. One could never get the insight and education in a new biotech that could parallel what has been offered here the past few years, shenanigans and all.
BTW, I have been following this board for 10 years, long enough to know that you have information (your own DD) way beyond what you have graciously offered to us.
Thank you for that.
Nice career opportunities available at Advent.....wondering what is happening.
https://adventbio.peoplehr.net/JobBoard/
You're welcome ds
ic....
You post for the satisfaction of “shock value” to others when, in fact, your posts stain your self value. How sad for you.
CVS and Walgreen Boots present health care plans at 2023 JP Morgan Healthcare Conference
https://biotechmetro.com/cvs-health-and-walgreens-boots-alliance-delivering-value-based-care/
I am asking the “more knowledgeable posters” on this board to review the linked post (6/26/2023) I found on the UK’s ATTC site and ascertain if this might have any relevance to NWBO as they await approval.
“Advanced Therapy Medicinal Products (ATMPs) aim to restore health following one time treatment. However, constraints that impede delivery have been identified across several parts of the pathway from manufacturer through to delivery sites.”
“Reviewing the Impact of Constraints on the Cost-effectiveness of Cell and Gene Therapies: A Systematic Review”
https://www.theattcnetwork.co.uk/imatch/reviewing-the-impact-of-constraints-on-the-cost-effectiveness-of-cell-and-gene-therapies-a-systematic-review
From Advent website: (Apologies if this posting is a duplicate)
https://www.adventbio.uk/post/advent-services
A keeper, thank you ATLnsider.
Interesting read:
“Responding to urgency to address unmet biomedical needs and the aspiration to pursue only the most audacious and impactful programs at ARPA-H’s founding, I outlined an approach to effectively communicate critical mission focus areas for investment and orchestrate how ARPA-H will determine the specific programs to fund. To frame this critical answer for our stakeholders, we developed four ARPA- H focus areas: Health Science Futures, Scalable Solutions, Proactive Health, and Resilient Systems.
These focus areas align with key areas where we believe big investment from ARPA-H can significantly advance the state of the art and even change the course of a particular field in a disease agnostic manner.”
Renee D. Wegrzyn, PhD - ARPA-H 2024
https://arpa-h.gov/assets/files/ARPA-H_FY_2024.pdf
Gold Star!!!
Of interest: AmplifyBio (CEO…J. Kelly Ganjei, previously CEO of Cognate) announces expansion of preclinical CRO into manufacturing.
https://www.amplify-bio.com/amplifybio-adds-manufacturing-capabilities-to-expand-service-portfolio/
OJ….
As I read your post, it occurred to me that I just reviewed an article about a company involved in solving the forever chemical problem. The company has been spun out of Battelle (battelle.org) The reason I was in the Battelle site is my NWBO DD steered me there as this company had recently spun out a pre-clinical CRO company in May 2021 called AmplifyBio (amplify-bio.com) whose CEO is J. Kelly Ganjei, previously CEO of Cognate Bio and, I believe, a previous senior team member of Toucan. Mr. Ganjei brought two of his senior management people from Cognate Bio with him to AmplifyBio. I have been following AmplifyBio since 2021; they are building their third site in Ohio and acquired their fourth site, an asset acquisition, in South San Francisco. But, for your info, if you haven’t seen it, the following is offered:
Battelle (Revive Environmental Technology)
https://www.battelle.org/insights/newsroom/press-release-details/revive-environmental-pfas-annihilator-deployed-in-first-to-market-commercial-destruction-of-forever-chemicals
Hope this is not an intrusion in your ongoing discussion. I enjoy your posts.
looks like my link was disabled.....try again
https://www.inmunebio.com/tmp/cfc740430ec7c787d8fd3cfe64021d72283f69ca3d62fc1b7291988cc7818622.pdf
As I am out of my league among the many selfless contributors on this msg board, I am unable to evaluate this latest news from INmune: So…intellects and professionals please give it a go.
Note: (1) Immune Ventures mentioned in the 8K was founded by Mark Lowdell, CMO/CSO of INmune Bio. (2) INKmune, subject of the 8K: INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. (3) Mark Lowdell is also a Director, Autolomous.
https://www.inmunebio.com/tmp/cfc740430ec7c787d8fd3cfe64021d72283f69ca3d62fc1b7291988cc7818622.pdf
Apologies if this was previously posted:
ASCO Honors Dr. Craig B. Thompson With the 2022 Science of Oncology Award
https://dailynews.ascopubs.org/do/asco-honors-dr-craig-b-thompson-2022-science-oncology-award
So very sorry to hear of your loss; it hurts the heart to read these stories.
“Never heard of EW healthcare. Looking at their list of past and current clients, I only seen one that i recognize Corium (past client), and that isn't even a big name. These guys are to consult for NWBO in management? Everyone knows NWBO need help there, but who is EW healthcare……"
May be of interest to you…..
https://www.ewhealthcare.com/news/detail/ew-healthcare-partners-acquires-germfree-laboratories-inc
Embattled regulator, Billy Dunn, to leave FDA
“Billy Dunn is leaving his post leading the FDA’s neuroscience team after an 18-year career that in recent years has included the controversial accelerated approval of Biogen’s Alzheimer’s med Aduhelm.”
https://www.fiercebiotech.com/biotech/dunn-fda-head-neuroscience-unit-depart
Re: Sashi Murthy….(1) Flashworks….(2) Nanite
Sashi Murthy is currently listed as a speaker at upcoming (Sept. 2023)
Bioprocess Intl in Boston with Flaskworks identity. Perhaps an earlier registration.
https://informaconnect.com/bioprocessinternational/speakers/shashi-murthy/
And
As Murthy is currently noted as co-founder of Nanite, developer of a new delivery system (Sayer) a separation of patent ownership was desired.
https://www.businesswire.com/news/home/20230215005050/en/Nanite-Debuts-AI-Driven-Polymer-Design-Platform-for-Gene-Delivery
Back pedaling….quietly seeking an exit door….slowly I turn.
IMO, of course.
“One funny meme in that video was:
Madoff: I went to jail because I stole from the top 1%.
Ken Griffin: I didn't go to jail because I steal from the 99%.”
The 1% have friends in high places.
The 99% are fodder
Of interest...INmune Bio, University of CA (Irvine)
INmune Bio 1.25.2023…forms subsidiary focused on Duchenne Muscular Dystrophy.
“The Company has formed a wholly owned subsidiary, DN02, Inc., that will hold rights to DMD-specific intellectual property and know-how. The subsidiary will facilitate partnering and business development activities for DMD without impacting the Company’s CNS programs.”
https://www.inmunebio.com/news-2/2023/515-muneioncnnouncesrelinicalatahatupporta20230125
Thanks, Flipper,I saw that Advent was listed as attending.
Interestingly enough, J. Kelly Ganjei, former CEO of Cognate BioServices and now CEO of AmplifyBio was a speaker at that event:
"2:05pm Presentation: The Product is the Product: The Challenge and Obligation
Responsible characterization
Refining the definition of drug safety
Embracing a future manufacturing standard
J Kelly Ganjei, President and Chief Executive Officer, Amplify Bio"
https://advancedtherapiesweek.phacilitate.com/stream/getting-to-commercial-manufacturing-producing-therapies-for-patient-need/